Unknown

Dataset Information

0

Current and Future Treatments in Alzheimer Disease: An Update.


ABSTRACT: Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research. Nowadays, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance: 3 cholinesterase inhibitors and memantine. To block the progression of the disease, therapeutic agents are supposed to interfere with the pathogenic steps responsible for the clinical symptoms, classically including the deposition of extracellular amyloid ? plaques and intracellular neurofibrillary tangle formation. Other underlying mechanisms are targeted by neuroprotective, anti-inflammatory, growth factor promotive, metabolic efficacious agents and stem cell therapies. Recent therapies have integrated multiple new features such as novel biomarkers, new neuropsychological outcomes, enrollment of earlier populations in the course of the disease, and innovative trial designs. In the near future different specific agents for every patient might be used in a "precision medicine" context, where aberrant biomarkers accompanied with a particular pattern of neuropsychological and neuroimaging findings could determine a specific treatment regimen within a customized therapeutic framework. In this review, we discuss potential disease-modifying therapies that are currently being studied and potential individualized therapeutic frameworks that can be proved beneficial for patients with AD.

SUBMITTER: Yiannopoulou KG 

PROVIDER: S-EPMC7050025 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Current and Future Treatments in Alzheimer Disease: An Update.

Yiannopoulou Konstantina G KG   Papageorgiou Sokratis G SG  

Journal of central nervous system disease 20200229


Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research. Nowadays, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance: 3 cholinesterase inhibitors and memantine. To block the progression of the disease, therapeutic agents are supposed to interfere with the pathogenic steps responsible for the clinical symptoms, classically including the deposition of extracellular amyloid β plaques and int  ...[more]

Similar Datasets

| S-EPMC4976881 | biostudies-other
| S-EPMC6571952 | biostudies-literature
| S-EPMC10824325 | biostudies-literature
| S-EPMC5516582 | biostudies-other
| S-EPMC4394625 | biostudies-literature
| S-EPMC6277282 | biostudies-literature
| S-EPMC7911353 | biostudies-literature
| S-EPMC7407591 | biostudies-literature
| S-EPMC8032930 | biostudies-literature
| S-EPMC4728993 | biostudies-literature